


EVERNORTH INTELLISPHERESM

Big Data, Bigger Possibilities



Product Overview

“The depth of the data available makes the tool so important.”

From a “very satisfied” Client user



Evernorth IntellisphereSM

Personalized application with deep analytic capabilities



“It’s so easy to run claim detail reports with a variety of ways to view the results and find what I need.”

– Comment from a “very satisfied” client user

Integrated Pharmacy + Medical Data

- + Access up to seven years of data containing more than 10B prescription claims, 300M patients, 3B medical claims, and 5M providers
- + Robust query abilities meshing pharmacy and medical claims data in the same query

Tailored Queries and Benchmarking

- + Highly customizable filters and criteria to allow you to choose your own adventure and analyze your data how you see fit
- + Benchmark providers and pharmacies against peers
- + Export any report

Personalization

- + Easily sortable, filterable, and exportable detailed views/reports
- + Customizable populations, filters, export columns, and more
- + Upload/Create provider, pharmacy, and patient cohorts
- + Upload lists of drugs, diagnosis and procedure codes

Identifying Opportunities Across Key Areas

Utilizing Integrated Pharmacy, Medical and Lab Data



Population Cost and Trend Identification



Social Determinant of Health



Identifying Gaps in Care



Provider Benchmarking



Total Cost of Care



Quality Care Management



Forecasting



PDC Forecasting

Adherence (PDC) Forecast

Built by Evernorth Research Institute Data Science Department, our predictive adherence model uses AI, machine learning, and large-scale forecasting algorithms to anticipate adherence. Predictions are not guaranteed but can provide guidance, enabling proactive outreach and smarter intervention.

Visit the Adherence Dashboard Forecast tab to view future models for your population. [View Details >](#)

Total Cost of Care for CardioDiabetes (Prior Year)

\$1,643,673k
Total Cost
488k Patients
44% Female Age 65+ Highest Cost Demographic

CardioDiabetes encompasses cardiovascular disease, diabetes, and obesity. Having one of these can often lead to future diagnoses of the others. [View Details >](#)

Social Determinants of Health (Rolling 12 Months)

U.S. State with the Highest Social Determinant Risk
State: California
County: Los Angeles

Category with highest risk
14.95% of population
Environment (Very High)

Definitions: A high ESD score means there are multiple social determinants of health factors negatively impacting the community/sensus tract. [View Details >](#)

Adherence (PDC) for Key Measures (Rolling 12 Months)

667,614 Top Opportunity Patients
Leverage insights to advance patients within PDC range 70-79% to achieve 80% target.

Nonadherence can be associated with higher rates of hospital admissions, suboptimal health outcomes, increased mortality and mortality, and increased health care costs. [View Details >](#)

Top Indications by Total Cost (Rolling 12 Months)

DIABETES: \$14.8 B
CANCER: \$12.8 B
INFLAMMATORY CONDITIONS: \$744.6 M
ANTICOAGULANT: \$702.2 M
MENTAL DISEASES: \$416.9 M

Top Trending Indications (Rolling 12 Months)

ALDHO: DEMIANTI, AMYLOIDOSIS, TARDIVE DYSKINESIA

Social Determinants of Health (SDH) by State and County

Determinants By PE: ESDI (0.15), Economy (0.17), Education (0.13), Infrastructure (0.14), Food Access (0.16), Health coverage (0.13), Culture (0.13), Environment (0.16), Population (0.14)

Please note: Risk evaluation and scoring are based on data provided by the US Census Bureau. This does not directly connect to your customers. This annual data is directional and per population in each county.

Top 5 Pipeline Drugs by Potential Cost

adiponitrile derivatives: \$468.5 M
hydroxylase oligopeptides: \$250.0 M
adiponitrile: \$192.3 M
hydroxylase: \$181.1 M
sildenafil: \$27.4 M

Summary

# of Drugs	# of Manufacturers	Estimated Cost	# of Conditions	# of Patients Utilizing Drug	Potential Cost	% Client Lives Involved
17	15	\$6,024M	16	2,459		0.16%

Detail

Pipeline Drug	Label	Formulation	Est. Cost	Anticipated Approval	Conditions	Unique Patient Count	Potential Cost	% Client Lives
diagononab derumcan	Acetaminophen	Hydroxylase (N)	\$625					0.08%

Total Cost of Care

Drivers of Total Cost by Major Medical Categories.

Population @ Major Categories Sub Category Conditions Body Location Age Gender

Major Categories by Total Cost and Total Cost Percentage

Total Plan Paid by Claim Type

574.0 K Patients
\$ 4.4 B Total Cost

Current Claims Information for Eligible Patients

Total Cost of Care Report Filter: Major Categories: All, Sub Category: (none), Dates: Rolling 6 months

Top Drug Indications by Total Plan Cost

Top Primary Medical Diagnosis Chapters

Adherence Dashboard (PDC)

Adherence by Therapeutic Class. You can filter your data by PDC range and other filters. Click here to view additional filters.

Population @ Date Range PDC Min PDC Max

Therapy Class

Patient Count by Adherence Therapy Class


Adherence Trend (Apr 2024 - Apr 2025)

Patient Count by Age & Gender

Patient Count by Channel

Continuous investment

Working with our clients on the right innovations



Looking Toward 2025


Current Features in Discovery

Anticipated Features

- + Diabetes Patient Identification
- + SDoH Overlay with Insights
- + Additional Integrated Reporting Views

Forecasting/Machine Learning

- + Diabetes Progression
- + Severe Complications



Social Determinants of Health (SDoH)

Social Determinants of Health is a composite score developed by Evernorth. The data is annual and reporting will give you patients who are eligible.

Population @ [] State [Arkans... x] County [Faulkner] Category [All] Score [All] **Run Report**

Social Determinants of Health (SDoH) by State and County

Heatmap View

Determinants By Percentage: ABC_Client State - Arkansas Region/County - Faulkner
Total Members in Range - 52

ESDI	30.77%	38.40%	30.77%
Economy	38.40%	26.92%	11.54%
Education	34.62%	65.38%	
Infrastructure	30.77%	69.23%	
Food access	34.62%	65.38%	
Health coverage	30.77%	30.77%	38.40%
Culture	34.62%	42.31%	23.08%
Environment	38.40%	11.54%	

Patient Name / ID	Adherence Scores	ESDI Overall in Patients City	Total Cost of Care Major Categories	Total Plan Cost RX	Total Plan Cost Med
ie Q 15678	Diabetes 72% Asthma & Allergy 80%	Very High	Cardiometabolic Urology	\$50,154	\$125,085
Smith 78912	Multiple Sclerosis 72%	Medium	Nervous System Dermatology	\$345,000	\$567,970




Prototypes – actual functionality may differ

Application Views

Intellisphere Home Page – Intelligent Insights

+ This view allows you to understand your population and targets important insights




Total Cost of Care

- + This view will let you see your patients and spend by medical condition.
- + This will expand to provide additional views by condition and more
- + 1 year of Medical Claims are required for this view



Social Determinants of Health

- + This view will let you see your patients in each county alongside their SDOH score for the county. This will help you understand potential impacts in specific areas
- + This will expand to provide additional views of potential impacts along with client lists



Pipeline Reporting

- + This view will let you see the potential impact of Specialty and Gene Therapy medications that are currently being reviewed by the FDA
- + Medical Claims are required for this view

Drug Pipeline
PowerPoint Learn More

Utilize filters below to view the potential cost and unique eligible patients through this dashboard.

Specialty
Gene & Cell Therapy
Gene & Cell Forecast

Population

Date Range

Last 12 Months (04/01/2024-03/31/2025)

Pipeline Drug

Selected (18)

Conditions

Selected (17)

Clear Filters

Run Report

Top 5 Pipeline Drugs by Potential Cost

Drug	Potential Cost
datopotamab deruxtecan	\$486.0 M
vusolimogene oderparepvec	\$100.0 M
odronextamab	\$93.2 M
zenocutuzumab*	\$92.1 M
tolebrutinib	\$37.4 M

Patient Pharmacy Utilization by MCI

Specialty Pipeline Drugs

Summary

# of Drugs	# of Manufacturers	Estimated Cost	# of Conditions	# of Patients Utilizing Drug	Potential Cost	% Client Lives Involved
17	15	\$6.03M	16	2,409		0.18%

Detail

Pipeline Drug	Labeler	Formulation	Est. Cost	Anticipated Approval	Conditions	Unique Patient Count	Potential Cost	% Client Lives
datopotamab deruxtecan	AstraZeneca	Intravenous (IV)		2025				0.08%

EVERNORTH
HEALTH SERVICES

1/22/2026

© 2025 Evernorth Health Services. Confidential, unpublished property of Evernorth Health Services. Do not duplicate or distribute. Use and distribution limited solely to authorized personnel.

11

Adherence Dashboard

- + This dashboard will allow you to select the PDC range that you want to review
- + You can also select individual adherence categories to dive into
- + From here you can run a report and get to the patient and provider level details

Adherence Dashboard (PDC)

Adherence PDC Specialty PDC Forecast **BETA**

Adherence by Therapeutic Class. You may filter your data by PDC range and other filters. Click More to view additional filters. [Learn More](#)

Population Date Range: Rolling 12 Months PDC Min: 70 PDC Max: 79 % Therapy Class: Selected (12) [More](#) [Clear](#) [Run Report](#)

Patient Count by Adherence Therapy Class

Therapeutic Class	Total Count
CHOLESTEROL/LIPIDS	30,117
STATINS	30,045
HYPERTENSION	27,139
RASA	22,197
ANTIDEPRESSANTS	16,280
ANTICOAGULANTS	10,433
DIABETES	9,760
INHALED CORTICOSTEROIDS	5,917
ANTIPSYCHOTICS	4,101
ANTIPLATELETS	3,954
OSTEOPOROSIS	3,395
LABA-LAAC	3,390

Adherence Trend (Apr 2024 - Apr 2025)

Data is updated twice per month for rolling 12 months.

Patient Count by Age & Gender

Patient Count by Channel

Adherence (PDC) Forecast

Adherence forecast based on prior performance.

Population: Test_Client Therapy Class: DIABETES

Provider Adherence

[Go Back](#) [Summary](#) [Detail](#)

Provider	Patient Name	Therapeutic Class	PDC Score	Avg Copay	Channel	Days Supply	New to Therapy?
		CHOLESTEROL/LIPIDS	80.0%	\$9	Ret30	30	N
		STATINS	80.0%	\$4	Ret90	90	N
		CHOLESTEROL/LIPIDS	80.0%	\$15	Mail	90	N
		HYPERTENSION	80.0%	\$7	Ret90	90	N

High-Cost Claimant

- + This dashboard will allow you view your high-cost claimants current utilization
- + Ability to select date options along with monitor specific patient lists
- + See top 50 utilizers, export results and select individual patient views

High-Cost Claimants BETA PowerPoint

Claims for eligible patients on both Medical and Rx with high plan cost

Population: [] Date range: Last 6 Months (10/01/2024-03/31/2025) Patient List: Patient List Total Plan Cost Range: Min \$ - Max \$ [More](#) [Clear Filters](#)

Rx and Medical Claims for Eligible Patients

Filters: MCI: - All, Chapters: - All, Sections: - All, Categories: - All

Top Indications by Cost (Pharmacy)

INFLAMMATORY CONDITIONS	\$1.3 B
DIABETES	\$1.3 B
CANCER	\$510.1 M
HIV	\$321.7 M
ATOPIC DERMATITIS	\$194.3 M
WEIGHT LOSS	\$194.0 M
MIGRAINE HEADACHES	\$174.6 M
MULTIPLE SCLEROSIS	\$143.5 M
ASTHMA	\$126.3 M
ANTICOAGULANT	\$112.4 M

Medical Diagnosis Plan Cost Claim Count

Above graph is for all the patients for the applied population and filter criteria.

Patient Profile Add to List

Patient ID (AGN): []
Population: []

Overview Eligibility Recent Claims Integrated Claims

Pharmacy & Medical - Last 12 months (04/30/2024 - 04/30/2025)

Top Indications by Cost (Pharmacy)

MUSCULAR DYSTROPHIES	\$176.2 K
HIGH BLOOD PRESS/HEART DISEASE	\$167.02
HEARTBURN/ULCER DISEASE	\$80.41
INFLAMMATION/IMMUNE DISORDERS	\$6.17
ALLERGIES	\$4.61

Medical Diagnosis Plan Cost Claim Count

Top 50 Patients with High cost claims Export List

Patient ID	Plan Cost(Rx)	Plan Cost(Medical)	Total Plan Cost
[]	\$87,055	\$3,601,571	\$3,688,626
[]	\$3,447	\$3,497,437	\$3,430,584

Surveillance Dashboard Uncovering Opportunities

- + Employ the Surveillance Dashboard to identify unwarranted variability
- + View by all rules or limit by Spike in Sum Paid Amount
- + Product has >100% spike in utilization over the last six months
- + View medications by all indications or narrow to fit your focus

Drug Filters

Filters [Clear all](#)

Narrow by Medication Surveillance Rule:

- Inflated Price by Indication
- Inflated Price by Route
- Inflated Price by Strength and Form
- Spike in Sum Paid
- High Independent Pharmacy Utilization



Apply

Medication Surveillance

Surveillance Drugs will be shown in dashboard. Use settings to change ⚙️

Population ⚙️
Date Range ⚙️
Provider Groups ①
DAW
↻
View Report

[Medication Surveillance](#) [About Surveillance](#)



Medication Surveillance



Surveillance Drugs will be shown in dashboard. Use settings to change ⚙️

Population ⚙️
Date Range ⚙️
Provider Groups ① ▾

DAW ▾ ↻

[View Report](#)

[Medication Surveillance](#) [About Surveillance](#)





Medication Surveillance

Surveillance Drugs will be shown in dashboard. Use settings to change ⚙️

Population ⚙️
Date Range Last Month (10/01/2023-10/31/2023) ▾
Provider Groups ① None ▾
DAW All ▾
↻

View Report

Medication Surveillance About Surveillance



Surveillance Dashboard

Related Providers					
Drug: RYBELSUS 7 MG TABLET					
Provider Name	Total Cost	Claim Count	Cost per Claim	Cost Per Days Supply	Patient Count
	\$682	2	\$341	\$68	1
	\$1,890	1	\$1,890	\$63	1
	\$681	1	\$681	\$60	1
	\$1,479	1	\$1,479	\$49	1

Related Pharmacies					
Drug: RYBELSUS 7 MG TABLET					
Pharmacy Name	Total Cost	Claim Count	Cost per Claim	Cost Per Days Supply	Patient Count
	\$682	2	\$341	\$68	1
	\$681	1	\$681	\$60	1
	\$1,479	1	\$1,479	\$49	1
	\$4,788	2	\$2,394	\$41	2

Related Patients					
Drug: RYBELSUS 7 MG TABLET					
Patient Name	Total Cost	Claim Count	Cost per Claim	Cost Per Days Supply	Pharmacy Count
	\$682	2	\$341	\$68	1
	\$1,890	1	\$1,890	\$63	1
	\$681	1	\$681	\$60	1
	\$1,479	1	\$1,479	\$49	1

- + Investigate Rybelsus claims in the Dashboard, or by viewing the report detailing the individual Prescribers, Patients, Pharmacies and Claims for Rybelsus
- + Uncover trends, top utilizers and outliers amongst these groups

Omission of Care Query

- + GLP-1s may have beneficial effect on weight, but only two have been approved for obesity in the US
- + The remaining GLP-1s are at risk of off-label prescribing
- + Identify potential FWA in top prescribers writing Mounjaro for members that do not have a diabetes diagnosis
- + Utilize the Omission of Care report to identify members filling Mounjaro claims that do not have a diabetes diagnosis or other diabetes medications
- + Individualize the report dates to pull Mounjaro use over the last 6 months, with no diabetes diagnosis over the last two years

Review Your Criteria and Run Report ⓘ *Required

▼ **POPULATION ***

Client Name Test_Client  

▼ **INCLUDE PATIENTS... ***

Trade Name Include RYBELSUS   

▼ **WITH the OMISSION ... ***

Medical Diagnosis E11: Type 2 diabetes mellitu...   

▼ **EXCLUDE PATIENTS ... (OPTIONAL)**

Clear Filters Run Report

High Claim Utilizers – Patient Breakdown View

- + This shows you a view of the patient details. With PHI access you will be able to see the patient's information, dive into more details and create patient lists to monitor all from a report view
- + You can also download this view to get to the claim level details

Custom Report Details - Add... Summary Summary ↓ Detail ↓

[Go Back](#)

Pharmacy Medical

Patient

[Reset Filters](#)

Patient Name	Most Common Indication	Provider Count	Pharmacy Count	Claim Count	Total Cost	Total Patient Cost	Cost per Claim	Cost Per Days Supply	Generic %	Mail %
Summary Expand all		136,778	17,824	2,674,620	\$510,889,815	\$38,291,342	\$191	\$4	81.9%	14.9%
+		4	5	15	\$376,460	\$19,829	\$25,097	\$450	53.3%	0.0%
+		2	3	6	\$371,310	\$0	\$61,885	\$1,340	50.0%	33.3%
+		1	2	4	\$340,534	\$1,050	\$85,134	\$2,647	0.0%	0.0%
+		1	1	6	\$328,555	\$0	\$54,759	\$3,911	0.0%	100.0%
+		1	2	20	\$319,297	\$0	\$15,965	\$538	70.0%	0.0%
+		5	2	23	\$307,163	\$0	\$13,355	\$211	78.3%	0.0%
+		1	1	4	\$295,755	\$0	\$73,939	\$3,521	0.0%	0.0%

High Claim Utilizers – Patient Breakdown View - Expanded

+ This shows you the expanded view from the prior page

Custom Report Details - Add... Summary Summary ↓ Detail ↓

[Go Back](#)

Pharmacy Medical

Patient Reset Filters

Patient Name	Most Common Indication	Drug Class (AHFS)	Brand Name	Drug Label	Provider Count	Pharmacy Count	Claim Count	Total Cost	Total Patient Cost	Cost per Claim	Cost Per Days Supply	Generic %	Mail %
Summary					136,778	17,824	2,674,620	\$510,889,815	\$38,291,342	\$191	\$4	81.9%	14.9%
Collapse all													
—					4	5	15	\$376,460	\$19,829	\$25,097	\$450	53.3%	0.0%
	— OPHTHALMIC CONDITIONS				1	2	4	\$374,623	\$19,717	\$93,656	\$4,695	0.0%	0.0%
		— EENT DRUGS, MISCELLANEOUS			1	2	4	\$374,623	\$19,717	\$93,656	\$4,695	0.0%	0.0%
			— TEPEZZA		1	2	4	\$374,623	\$19,717	\$93,656	\$4,695	0.0%	0.0%
				TEPEZZA 500 MG VIAL	1	2	4	\$374,623	\$19,717	\$93,656	\$4,695	0.0%	0.0%
	+ DIABETES				1	2	4	\$1,517	\$84	\$379	\$5	50.0%	0.0%
	+ HIGH BLOOD PRESS/HEART DISEASE				1	2	3	\$162	\$16	\$54	\$1	100.0%	0.0%
	+ VACCINATIONS				1	1	1	\$108	\$0	\$108	\$4	0.0%	0.0%
	Show More												
+					2	3	6	\$371,310	\$0	\$61,885	\$1,340	50.0%	33.3%
+					1	2	4	\$340,534	\$1,050	\$85,134	\$2,847	0.0%	0.0%
+					1	1	6	\$328,555	\$0	\$54,759	\$3,911	0.0%	100.0%
+					1	2	20	\$319,297	\$0	\$15,965	\$538	70.0%	0.0%

Detail Report Views by Drug, Provider and Pharmacy

Pharmacy Medical

Drug

[Reset Filters](#)

Most Common Indication	Patient Count	Provider Count	Claim Count	Total Cost	Total Patient Cost	Cost per Claim	Cost Per Days Supply	Generic %	Mail %
Summary Expand all	489,468	136,778	2,674,620	\$510,889,815	\$38,291,342	\$191	\$4	81.9%	14.9%

- + DIABETES
- + CANCER
- + INFLAMMATORY CONDITIONS
- + HIV

Pharmacy Medical

Provider

[Reset Filters](#)

Provider Name	Most Common Indication	Patient Count	Claim Count	Total Cost	Total Patient Cost	Cost per Claim	Cost Per Days Supply	Generic %	Mail %
Summary Expand all		489,468	2,674,620	\$510,889,815	\$38,291,342	\$191	\$4	81.9%	14.9%
+ [Redacted]		13,937	18,001	\$2,036,714	\$2,846	\$113	\$113	0.0%	0.0%

Pharmacy Medical

Pharmacy

[Reset Filters](#)

Pharmacies	Patient Count	Claim Count	Total Cost	Total Patient Cost	Cost per Claim	Cost Per Days Supply	Generic %	Mail %
Summary Expand all	489,468	2,674,620	\$510,889,815	\$38,291,342	\$191	\$4	81.9%	14.9%
+ [Redacted]	110,273	347,623	\$77,016,791	\$6,616,604	\$222	\$3	79.0%	100.0%
+ [Redacted]	5,583	10,604	\$71,378,788	\$1,874,261	\$6,731	\$155	13.9%	100.0%
+ [Redacted]	847	1,402	\$10,249,611	\$267,577	\$7,311	\$196	9.4%	0.0%
+ [Redacted]	524	1,960	\$7,034,153	\$219,002	\$3,589	\$108	42.7%	0.0%

Detail Report Views of Medical Claims

Custom Report Details - Add Summary Detail

[Go Back](#)

Pharmacy Medical

Patient	Medical Claim #	Service Date	Provider/Facility	Claim Type	Code	Description	Site of Care	Billed Amount	Allowed Amount	Plan Paid	Copay	Coinsurance	Deductible
-													
	-	09/28/2023		PDX	R10.811	RIGHT UPPER QUADRANT ABD TENDERNESS							
		09/28/2023		PDX	R10.811	Right upper quadrant abdominal tenderness							
		09/28/2023		CPT	36415	COLLECTION VENOUS BLOOD VENIPUNCTURE	Office						
		09/28/2023		CPT	99213	OFFICE/OUTPATIENT ESTABLISHED LOW MDM 20-29 MIN	Office						
		09/28/2023		HCPCS	1036F	CURRENT TOBACCO NON-USER CAD CAP COPD PV DM	Office						
	+	09/28/2023		PDX	R10.811	RIGHT UPPER QUADRANT ABD TENDERNESS							
	+	09/27/2023		PDX	R10.11	RIGHT UPPER QUADRANT PAIN							
	+	09/18/2023		PDX	M06.9	RHEUMATOID ARTHRITIS UNSPECIFIED							
	+	08/24/2023		PDX	Z23	ENCOUNTER FOR IMMUNIZATION							
						Show More							
-													
	-	08/29/2023		PDX	Z23	ENCOUNTER FOR IMMUNIZATION							
		08/29/2023		PDX	Z23	Encounter for immunization							
		08/29/2023		CPT	90715	TDAP VACCINE 7 YRS/> IM	Office						
		08/29/2023		CPT	90460	IM ADM THRU 18YR ANY RTE 1ST/ONLY COMPT VAC/TOX	Office						
		08/29/2023		CPT	90461	IM ADM THRU 18YR ANY RTE ADDL VAC/TOX COMPT	Office						

Provider and Pharmacy Insight Reporting

- + Provider and Pharmacy Insight Reports show the basic details about their location, specialties and affiliations from NPPES
- + All of this can be found by searching for a specific provider or pharmacy or directly from any report you run
- + List capabilities allows you to create provider and pharmacy cohorts to use throughout the application
- + You also then further understand their prescribing/filling habits by reviewing the available tabs in the report below.
- + These are benchmarked against providers across their state and national level
- + You can also benchmark them against a customized list of providers or pharmacies to see how they compare

Provider Profile

[Redacted]

NPI #: [Redacted]

Names & Locations **Specialties** Affiliations

Category	Specialty	Subspecialty	Taxonomy Code
Allopathic & Osteopathic Physicians	Internal Medicine	Cardiovascular Disease	207RC0000X

Provider Insights

[Redacted] (+)

NPI #: [Redacted]
Internal Medicine

Populations: ABC...Client

Export Info

Specialty:

Adherence Generic Utilization Therapeutic Categories Specialty Drugs Mail Retail Patient Distance DEA DAW Patient Age & Gender

Adherence is always based on a Rolling 12 months

Providers	Diabetes	Statins	RASA	Cholesterol/Lipids	Hypertension	Anticoagulants	Inhaled Corticosteroids	LABA-LAAC	Antidepressants	Antipsychotics	Osteoporosis	Antiplatelets
Provider	100%	100%		100%	66.7%	0%						
State	77.3%	81.2%	84%	81.5%	84.2%	76.8%	38.8%	54.9%	74.3%	64.3%	75.7%	78.5%
National	76.1%	79.1%	80.4%	79.3%	79.1%	73.7%	36%	51.7%	69.2%	55.8%	74%	76.4%

Patient Profile View

- + Patient Profiles are available to any user that is granted PHI access
- + All of this can be found by searching for a specific patient or directly from any report you run
- + You then further understand their prescribing/filling habits by reviewing the available tabs in the report below.
- + Here you can view their eligibility information
- + List capabilities provide the ability to create patient cohorts to be utilized throughout the application

Patient Profile + Add to List

[Redacted]

Patient ID (AGN): [Redacted]
Population: [Redacted]

Overview Eligibility Recent Claims

Overview

Age:	22
Gender:	F
Date of Birth:	[Redacted]
Address:	[Redacted]
City:	[Redacted]
County:	[Redacted]
State:	[Redacted]
Zip Code:	[Redacted]

Patient Profile + Add to List

[Redacted]

Overview Eligibility Recent Claims

Eligibility Information

Eligibility Status:	Active
Effective Dates:	01/01/2025 - 12/31/2028
Patient ID (AGN):	[Redacted]
Client Membership ID:	[Redacted]
Subscriber Client ID:	[Redacted]
Person Number:	[Redacted]
Client Name:	Test_Client
Client Org ID:	[Redacted]
Carrier ID:	[Redacted]
Group ID:	[Redacted]
Master Group:	[Redacted]
Client Contract ID:	[Redacted]
Line of Business:	Commercial

Patient ID (AGN): [Redacted]
Population: [Redacted]

Overview Eligibility Recent Claims

View: Staged claims Billed / Invoiced claims

Recent Claims

Zoom 1m 3m 6m YTD 1y All

	October	January	February	March	April	May	June	July	August
Pharmacy Claims	[Blue bar]								
SLEEP DISORDERS	[Green bar]								
NON-BENZODIAZEPINE HYPNOTICS	[Orange bar]								
ZOLPIDEM TARTRATE	[Teal bar]								
ZOLPIDEM TARTRATE 10 MG TABLET	[Yellow bar]								
Sep 9, 2023 - Sep 24, 2023	[Blue bar]								
Oct 7, 2023 - Oct 22, 2023	[Red bar]								

Custom Query Capabilities

Our core query capabilities are the brains of our application. You can start at the highest level with our dashboards and then drive into the details here.

	 Custom Report: Utilize filters to identify Providers, Pharmacies, Patients and Drugs	 Concomitant Therapy: Identify evidence of treatments occurring at the same time	 Omission of Care: Evidence of a condition and absence of treatment
Features	<ul style="list-style-type: none"> + Include and exclude filters + Refine results with multiple filters + Upload lists of providers, patients, NDC, & GCN's as well as create them from your results 	<ul style="list-style-type: none"> + Concomitant conditions + Include and exclude filters + Unique timeframes for each filter + Overlapping days supply and timeframe (Ex. 30, 60, 90 days) 	<ul style="list-style-type: none"> + Omission conditions + Include and exclude filters + Select different timeframes for each filter
Examples	<ul style="list-style-type: none"> + <i>Maintenance medications filled for 30 days at retail</i> + <i>Potential FWA concern foot bath compounds written in the Midwest but filled at Texas pharmacies</i> + <i>Multi-source brand name Acne medications costing >\$500/claim</i> 	<ul style="list-style-type: none"> + <i>Therapeutic duplications (ACE and ARB, multiple NSAIDs, include combination meds)</i> + <i>Major drug interactions</i> + <i>Opioids used with other respiratory suppressants in older adults</i> + <i>GLP1 and DPP4 combos</i> 	<ul style="list-style-type: none"> + <i>Diabetes diagnosis without a statin</i> + <i>Remicade not provided in an office</i> + <i>Rheumatoid Arthritis diagnosis without a disease modifying drug</i> + <i>Ozempic claims without a diabetes diagnosis (off-label use)</i>

Thank you

